In central obesity, weight loss restores platelet sensitivity to nitric oxide and prostacyclin

Obesity (Silver Spring). 2010 Apr;18(4):788-97. doi: 10.1038/oby.2009.302. Epub 2009 Oct 15.

Abstract

Central obesity shows impaired platelet responses to the antiaggregating effects of nitric oxide (NO), prostacyclin, and their effectors--guanosine 3',5'-cyclic monophosphate (cGMP) and adenosine 3',5'-cyclic monophosphate (cAMP). The influence of weight loss on these alterations is not known. To evaluate whether a diet-induced body-weight reduction restores platelet sensitivity to the physiological antiaggregating agents and reduces platelet activation in subjects affected by central obesity, we studied 20 centrally obese subjects before and after a 6-month diet intervention aiming at reducing body weight by 10%, by measuring (i) insulin sensitivity (homeostasis model assessment of insulin resistance (HOMA(IR))); (ii) plasma lipids; (iii) circulating markers of inflammation of adipose tissue and endothelial dysfunction, and of platelet activation (i.e., soluble CD-40 ligand (sCD-40L) and soluble P-selectin (sP-selectin)); (iv) ability of the NO donor sodium nitroprusside (SNP), the prostacyclin analog Iloprost and the cyclic nucleotide analogs 8-bromoguanosine 3',5'-cyclic monophosphate (8-Br-cGMP) and 8-bromoadenosine 3',5'-cyclic monophosphate (8-Br-cAMP) to reduce platelet aggregation in response to adenosine-5-diphosphate (ADP); and (v) ability of SNP and Iloprost to increase cGMP and cAMP. The 10 subjects who reached the body-weight target showed significant reductions of insulin resistance, adipose tissue, endothelial dysfunction, and platelet activation, and a significant increase of the ability of SNP, Iloprost, 8-Br-cGMP, and 8-Br-cAMP to reduce ADP-induced platelet aggregation and of the ability of SNP and Iloprost to increase cyclic nucleotide concentrations. No change was observed in the 10 subjects who did not reach the body-weight target. Changes of platelet function correlated with changes of HOMA(IR). Thus, in central obesity, diet-induced weight loss reduces platelet activation and restores the sensitivity to the physiological antiaggregating agents, with a correlation with improvements in insulin sensitivity.

Publication types

  • Controlled Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenosine Diphosphate / pharmacology
  • Adipose Tissue / metabolism
  • Adult
  • Blood Platelets / drug effects*
  • Cyclic AMP / metabolism
  • Cyclic GMP / metabolism
  • Diet, Reducing
  • Endothelium, Vascular / physiopathology
  • Epoprostenol / pharmacology
  • Female
  • Humans
  • Iloprost / pharmacology
  • Insulin Resistance*
  • Male
  • Nitric Oxide / metabolism*
  • Nitroprusside / pharmacology
  • Obesity, Abdominal / diet therapy
  • Obesity, Abdominal / physiopathology*
  • Platelet Activation / drug effects*
  • Platelet Aggregation Inhibitors / pharmacology*
  • Weight Loss / physiology*

Substances

  • Platelet Aggregation Inhibitors
  • Nitroprusside
  • Nitric Oxide
  • Adenosine Diphosphate
  • Epoprostenol
  • Cyclic AMP
  • Cyclic GMP
  • Iloprost